carmustine has been researched along with Mucositis in 11 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The median VAS scores of all patients were above 4 (moderate to severe pain) before the administration of transdermal fentanyl." | 7.74 | [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation]. ( Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Lin, XB; Peng, YL; Wang, BF, 2007) |
| "With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation." | 5.15 | A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. ( Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH, 2011) |
| " The median VAS scores of all patients were above 4 (moderate to severe pain) before the administration of transdermal fentanyl." | 3.74 | [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation]. ( Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Lin, XB; Peng, YL; Wang, BF, 2007) |
| "Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
| "Melphalan dose was used as surrogate for the entire regimen." | 1.35 | Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. ( Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF, 2008) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Ahern, K | 1 |
| Pham, J | 1 |
| Sanderson, R | 1 |
| Correia De Farias, M | 1 |
| Walsh, K | 1 |
| AlJohani, NI | 1 |
| Nasani, M | 1 |
| Ahmed, HE | 1 |
| Ur Rehman, J | 1 |
| Nawaz, A | 1 |
| Alzahrani, Z | 1 |
| Albeirouti, B | 1 |
| Mikesch, JH | 1 |
| Kuhlmann, M | 1 |
| Demant, A | 1 |
| Krug, U | 1 |
| Thoennissen, GB | 1 |
| Schmidt, E | 1 |
| Kessler, T | 1 |
| Schliemann, C | 1 |
| Pohlen, M | 1 |
| Mohr, M | 1 |
| Evers, G | 1 |
| Köhler, G | 1 |
| Wessling, J | 1 |
| Mesters, R | 1 |
| Müller-Tidow, C | 1 |
| Berdel, WE | 1 |
| Thoennissen, NH | 1 |
| Herbers, AH | 1 |
| van der Velden, WJ | 1 |
| de Haan, AF | 1 |
| Donnelly, JP | 1 |
| Blijlevens, NM | 1 |
| Tsirigotis, P | 1 |
| Triantafyllou, K | 1 |
| Girkas, K | 1 |
| Giannopoulou, V | 1 |
| Ioannidou, E | 1 |
| Chondropoulos, S | 1 |
| Kalli, T | 1 |
| Papaxoinis, G | 1 |
| Pappa, V | 1 |
| Papageorgiou, E | 1 |
| Economopoulos, T | 1 |
| Ladas, SD | 1 |
| Dervenoulas, J | 1 |
| Costa, LJ | 1 |
| Micallef, IN | 1 |
| Inwards, DJ | 1 |
| Johnston, PB | 1 |
| Porrata, LF | 1 |
| Litzow, MR | 1 |
| Ansell, SM | 1 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Phillips, GL | 1 |
| Bernstein, SH | 1 |
| Liesveld, JL | 1 |
| Abboud, CN | 1 |
| Becker, MW | 1 |
| Constine, LS | 1 |
| Ifthikharuddin, JJ | 1 |
| Loughner, JE | 1 |
| Milner, LA | 1 |
| Vesole, DH | 1 |
| Friedberg, JW | 1 |
| Bruserud, O | 1 |
| Reikvam, H | 1 |
| Kittang, AO | 1 |
| Ahmed, AB | 1 |
| Tvedt, TH | 1 |
| Sjo, M | 1 |
| Hatfield, KJ | 1 |
| Su, L | 1 |
| Xu, J | 1 |
| Ji, BX | 1 |
| Wan, SG | 1 |
| Lu, CY | 1 |
| Dong, HQ | 1 |
| Yu, YY | 1 |
| Lu, DP | 1 |
| Huang, HQ | 1 |
| Cai, QQ | 1 |
| Lin, XB | 1 |
| Wang, BF | 1 |
| Bu, Q | 1 |
| Gao, Y | 1 |
| Peng, YL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carmustine and Mucositis
| Article | Year |
|---|---|
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
1 trial available for carmustine and Mucositis
| Article | Year |
|---|---|
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmus | 2011 |
9 other studies available for carmustine and Mucositis
| Article | Year |
|---|---|
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Human | 2023 |
Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study.
Topics: Bendamustine Hydrochloride; Cardiotoxicity; Carmustine; Hematopoietic Stem Cell Transplantation; Hum | 2021 |
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Co | 2013 |
Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; C-Reactive Prot | 2014 |
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capsule Endoscopy; Carmustine; Cytarabi | 2008 |
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Dis | 2008 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Diarr | 2006 |
[Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Antineoplastic Combined Chemothera | 2007 |